Major Depressive

• Helus Pharma presented new analyses of its HLP003 drug candidate for Major Depressive Disorder at Psych Congress 2026. • The company used poster presentations to detail the clinical profile of HLP003 and its Phase 3 PARADIGM program for adjunctive treatment. • These results provide early data for a potential new treatment option, though the FDA and Health Canada have not yet evaluated or approved the drug's efficacy.

• Helus Pharma has completed enrollment ahead of schedule for the Phase 3 APPROACH study, which evaluates HLP003 as an adjunctive treatment for Major Depressive Disorder. • The company is continuing enrollment for EMBRACE, a second pivotal study within the Phase 3 PARADIGM Program, while rolling participants into the EXTEND study for long-term safety data. • This milestone is significant as HLP003 has previously been granted Breakthrough Therapy designation, signaling its potential to provide substantial improvement over existing therapies.